JP2018537100A - 抗ｔｎｆ療法に対する応答を予測する方法 - Google Patents

抗ｔｎｆ療法に対する応答を予測する方法 Download PDF

Info

Publication number
JP2018537100A
JP2018537100A JP2018529050A JP2018529050A JP2018537100A JP 2018537100 A JP2018537100 A JP 2018537100A JP 2018529050 A JP2018529050 A JP 2018529050A JP 2018529050 A JP2018529050 A JP 2018529050A JP 2018537100 A JP2018537100 A JP 2018537100A
Authority
JP
Japan
Prior art keywords
subject
target molecule
tnf therapy
sample
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018529050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537100A5 (enExample
Inventor
ルイーズ ライト ヘレン
ルイーズ ライト ヘレン
ジョン ムーツ ロバート
ジョン ムーツ ロバート
ウィリアム エドワーズ スティーブン
ウィリアム エドワーズ スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool filed Critical University of Liverpool
Publication of JP2018537100A publication Critical patent/JP2018537100A/ja
Publication of JP2018537100A5 publication Critical patent/JP2018537100A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Signal Processing (AREA)
  • Biomedical Technology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018529050A 2015-12-03 2016-12-02 抗ｔｎｆ療法に対する応答を予測する方法 Pending JP2018537100A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1521357.2 2015-12-03
GBGB1521357.2A GB201521357D0 (en) 2015-12-03 2015-12-03 Methods for predicting response to anti-TNF therapy
PCT/GB2016/053798 WO2017093750A1 (en) 2015-12-03 2016-12-02 Methods for predicting response to anti-tnf therapy

Publications (2)

Publication Number Publication Date
JP2018537100A true JP2018537100A (ja) 2018-12-20
JP2018537100A5 JP2018537100A5 (enExample) 2020-01-16

Family

ID=55234362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529050A Pending JP2018537100A (ja) 2015-12-03 2016-12-02 抗ｔｎｆ療法に対する応答を予測する方法

Country Status (8)

Country Link
US (1) US20190367984A1 (enExample)
EP (1) EP3384044A1 (enExample)
JP (1) JP2018537100A (enExample)
CN (1) CN108291261A (enExample)
AU (1) AU2016364003A1 (enExample)
CA (1) CA3005695A1 (enExample)
GB (1) GB201521357D0 (enExample)
WO (1) WO2017093750A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550439A (ja) * 2019-10-04 2022-12-01 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
WO2019018440A1 (en) * 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
CN108047327B (zh) * 2017-11-29 2020-08-07 中国医学科学院北京协和医院 一种检测骨关节炎的生物标志物及其应用
US20200399698A1 (en) * 2018-02-19 2020-12-24 Genefron Ltd. Methods of determining response to tnf alpha blockers
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
US20210104321A1 (en) * 2018-11-15 2021-04-08 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
KR20230165746A (ko) * 2020-11-30 2023-12-05 민데라 코포레이션 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이
WO2022190036A2 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Methods for predicting treatment response in ulcerative colitis
CN113373218A (zh) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 一组检测人嗜酸性粒细胞阳离子蛋白mRNA表达的引物组和试剂盒

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008487A2 (en) * 2006-07-13 2008-01-17 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
WO2010060999A1 (en) * 2008-11-27 2010-06-03 Vereniging Vu-Windesheim (Short Name) Predicting clinical response to treatment with a soluble tnf-antagonist, or tnf, or a tnf receptor agonist
JP2010529464A (ja) * 2007-06-08 2010-08-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
JP2013503643A (ja) * 2009-09-03 2013-02-04 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2014060785A2 (en) * 2012-10-19 2014-04-24 Egis Pharmaceuticals Public Limited Company DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
US20140135225A1 (en) * 2012-11-15 2014-05-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130042333A1 (en) * 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008487A2 (en) * 2006-07-13 2008-01-17 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
JP2010529464A (ja) * 2007-06-08 2010-08-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
JP2014033676A (ja) * 2007-06-08 2014-02-24 Biogen Idec Ma Inc 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
WO2010060999A1 (en) * 2008-11-27 2010-06-03 Vereniging Vu-Windesheim (Short Name) Predicting clinical response to treatment with a soluble tnf-antagonist, or tnf, or a tnf receptor agonist
JP2013503643A (ja) * 2009-09-03 2013-02-04 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2014060785A2 (en) * 2012-10-19 2014-04-24 Egis Pharmaceuticals Public Limited Company DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
US20140135225A1 (en) * 2012-11-15 2014-05-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS & RHEUMATOLOGY, vol. 67, no. 7, JPN6020033370, 2014, pages 1922 - 1932, ISSN: 0004339532 *
ARTHRITIS RESEARCH AND THERAPY, vol. 10, no. 3, JPN6020033362, 2008, pages 50, ISSN: 0004339525 *
AUTOIMMUNITY, vol. 40, no. 3, JPN6020033363, 2007, pages 191 - 201, ISSN: 0004339526 *
CYTOKINE, vol. 70, JPN6020033366, 2014, pages 51, ISSN: 0004339529 *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 700, JPN6020033364, 2013, pages 134 - 146, ISSN: 0004339527 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 9, JPN6020033367, 2014, pages 5960 - 5969, ISSN: 0004339530 *
JOURNAL OF IMMUNOLOGY, vol. 187, JPN6020033368, 2011, pages 538 - 552, ISSN: 0004339531 *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. vol.133, Suppl 1, JPN6020033365, 2013, pages 220, ISSN: 0004339528 *
RHEUMATOLOGY, vol. 54, JPN6020033361, 2015, pages 188 - 193, ISSN: 0004339524 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550439A (ja) * 2019-10-04 2022-12-01 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法

Also Published As

Publication number Publication date
CN108291261A (zh) 2018-07-17
US20190367984A1 (en) 2019-12-05
AU2016364003A1 (en) 2018-06-28
GB201521357D0 (en) 2016-01-20
WO2017093750A1 (en) 2017-06-08
EP3384044A1 (en) 2018-10-10
CA3005695A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
JP2018537100A (ja) 抗ｔｎｆ療法に対する応答を予測する方法
EP2337864B1 (en) Biomarkers for predicting the development of chronic autoimmune diseases
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
JP6097388B2 (ja) インフルエンザにおけるリスクの階層化
CA2889087C (en) Diagnostic method for predicting response to tnf.alpha. inhibitor
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
US11525161B2 (en) Methods of distinguishing ischemic stroke from intracerebral hemorrhage
US10793911B2 (en) Host DNA as a biomarker of Crohn's disease
US20220291238A1 (en) Methods for Predicting Treatment Response in Ulcerative Colitis
JP6347477B2 (ja) 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法
US20220351806A1 (en) Biomarker Panels for Guiding Dysregulated Host Response Therapy
EP3146072B1 (en) Circulating mirnas as biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-tnfalpha
JP2013021932A (ja) 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法
Pan Development of diagnostic methods using cell-free nucleic acids
EP4455308A1 (en) Il-7r gene signatures
Miyamoto et al. Current Overview of Multi-omics Analyses in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
US20210255199A1 (en) Prediction of drug-free remission in rheumatoid arthritis
Pitaksalee Rheumatoid arthritis: alterations in DNA methylation patterns in CD4+ T-cells: Understanding pathogenesis and developing a qMSP biomarker for classification
WO2022212890A1 (en) Companion diagnostic and therapies for dysregulated host response
Sutherland Optimization of circulating miRNA library preparation for next-generation sequencing and an exploratory pharmacogenomics investigation of psoriatic arthritis patients treated with IL-12/23 or IL-17 inhibitors
Allantaz-Frager et al. Identification of Biomarkers of Response to IFNg during Endotoxin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210330